Prognostic Value of the Lung Immune Prognostic Index in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab: A Real-World Analysis Beyond PD-L1 Expression. (PubMed, Diagnostics (Basel)) - Sep 27, 2026 - "Its association remained after adjustment for available PD-L1 expression data, and its addition improved model discrimination. These findings suggest that LIPI may provide prognostic information complementary to PD-L1 expression and routinely available clinical factors."
IO biomarker • Journal • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1
|
|
Aykut Özmen; Gökmen Umut Erdem; Nilüfer Bulut; Shamkal Safarov; Özde Melisa Celayir
|